MYCN and neuroblastoma: One of the most well‐known prognostic indicators for neuroblastoma is genomic amplification of MYCN (Homo sapiens v‐myc myelocytomatosis viral‐related oncogene, neuroblastoma derived), present in ~20% of patients.